score distributions and indices of reliability and validity. **RESULTS:** The literature review and in-depth semi-structured interviews of patients indicated that HSIA and HSSA are easily understood by patients and characterize their condition well. Forty subjects completed the observational study (females = 58%, Caucasian = 65%, and age [mean] = 41 years). HSIA and HSSA scores were well psychologically, with strong evidence of test-retest (ICC = 0.92 and 0.80, respectively) and internal consistency (α = 0.97 and 0.96, respectively) reliability and known groups (P < 0.001 and P < 0.006, respectively) and construct-related validity (via correlations between the other psychometric measures). Other: CONCLUSIONS: There is robust evidence supporting the HSIA and HSSA as content valid and psychometrically sound questionnaires for assessing symptoms and impacts in patients with HS.

**PSS30**

**SENSITIVITY OF FUNCTIONAL READING INDEPENDENCE (FRI) INDEX TO CHANGE IN SIZE OF GEOGRAPHIC ATROPHY**

Kapre AW1, Kimel M2, Bressler N3, Varma R4, Souied EH5, Dolan CS, Tischok E, Leidy N6
1Genentech, South San Francisco, CA, USA, 2University of Southern California, Los Angeles, CA, USA, 3University School of Medicine, Baltimore, MD, USA, 4UC Irvine Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA, 5Centre Hospitalier Intercommunal, Paris, France, 6Abacus International, Manchester, UK

**OBJECTIVES:** Visual acuity does not fully capture the effect of geographic atrophy (GA) on patients’ daily life. This study aimed to characterize the sensitivity of the Functional Reading Independence (FRI) Index to changes in GA size.

**METHODS:** A 7-item patient-reported measure (FRI Index) was translated into universal Spanish according to industry standard methodology. The FRI Index is a 7-item patient-reported measure developed for use in GA trials. This study examined the sensitivity of the FRI index to changes in GA size. A study approach to the translation of the FRI Index from MAHALO, a phase 2 study of lampalizumab, a complement factor monoclonal antibody fragment, for treatment of GA. For each reading activity performed in the past 3 months, patients were asked to rate the extent to which they required vision aids, adjustments in the activity, or help from another person. The FRI Index yields continuous mean scores (range 1-4) and ordinal level scores (from Level 1: Unable to do to Level 4: Totally Independently). Analysis of change in the FRI Index scores stratified by more (≧0.94mm²/yr) vs less (<0.94mm²/yr) GA lesion growth.

**RESULTS:** At 18 months, the mean change in FRI index score (SD) from baseline for patients with more lesion size growth was 3.0 (0.5, n = 13) vs 0.7 (0.7, n = 42) for patients with less growth (P < 0.02). For patients with more growth, 36% declined ≥ 1 FRI Level vs 15% for less growth. Excluding patients at FRI Level 1 at baseline, 41% of patients with more growth (N=54) declined > 1 FRI Level vs 18% with less growth (N=11).

**CONCLUSIONS:** In MAHALO, the mean FRI Index score of 0.9 differentiated patients with more vs less growth of GA lesion size. FRI level scores were also sensitive to GA lesion growth. These results provide evidence that patient-reported functional reading independence as measured by the FRI Index is linked to GA lesion growth, an objective clinical measure of disease progression.

**PSS31**

**DEMONSTRATING CONCEPTUAL EQUIVALENCE: TRANSLATION OF THE URTICARIA ACTIVITY AND IMPACT MEASURE (U-AIM) FROM ENGLISH INTO SPANISH**

Fernández-Varela F1, Antonova EN2, Arnold B3, Perez B4, Zazasli I5
1FACTTrans, Elmhurst, IL, USA, 2Genentech, Inc., South San Francisco, CA, USA

**OBJECTIVES:** Translation and linguistic validation of patient reported outcomes (PRO) measures is an essential component of health research methodology in preparation for multinationally marketed medical products. The Urticaria Activity and Impact Measure (U-AIM) is an instrument to assess the impact of urticaria on the patient’s viewpoint. The objective of this work was to translate and linguistically validate the U-AIM from English to Spanish for use with patients with urticaria.

For the purpose of the study, the U-AIM was translated into universal Spanish according to industry standard methodology. After the translation was completed, five Spanish-speaking patients in the US diagnosed with chronic idiopathic urticaria completed the translated questionnaire and participated in a cognitive debriefing interview.

Interviews were conducted using a standardized guide to assess the relevance, understandability, and appropriateness of the translations. Qualitative analyses were performed to ensure equivalence and that the content validity of the U-AIM was maintained for the Spanish version. **RESULTS:** Of the five patients (40% male), the mean age of four was 37 years [one patient did not report his age]. All U-AIM items were well understood and proved relevant to the patients in this sample. Of interest, terms such as, “urticaria,” “hives,” “angioedema,” and “rapid swelling” were clearly understood as intended.

**CONCLUSIONS:** The results indicate that the Spanish version of the U-AIM translation is conceptually equivalent to the English source version and easily understood by the target population in the US.

We consider the translation to be acceptable for PRO assessment in research and clinical practice. Future research could include testing of the PRO assessment in patients in other Spanish-speaking countries to confirm its acceptability beyond the US.

**PSS32**

**PATIENT REPORTED OUTCOMES IN GLAUCOMA A SYSTEMATIC REVIEW**

Clemente LM1, Topilsky Y2, Schiavon SM3
1Novel, Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

**OBJECTIVES:** Patient reported outcomes (PRO) are becoming useful tools for collecting and generating meaningful patient generated data. The new medical products are expected to show improvement in patient related quality of life (HRQoL). Glaucoma is a chronic disease with high importance for patient HRQoL. The objective of this study was to review, analyze, and understand trends in the PRO instruments used in patients with glaucoma.

**METHODS:** Systematic literature search for Glaucoma trials with PRO endpoints was undertaken for the databases Pubmed, Embase, Biois, Google Scholar and Cochrane. Data was gathered from the year 2000 to the year 2020. Analysis for conducted to identify trends in commonly used PRO instruments and categorize results as positive, neutral or negative. **RESULTS:** 31 studies with a total of 9819 patients were identified. In these studies there were eleven different PROs instruments used. Health related quality of life questionnaire (Glau-Qol), Glaucoma utility index, Impact of vision impairment, Low vision quality of life questionnaire, National eye institute visual function index (VFQ), Core outcomes set in glaucoma index and outcomes of glaucoma surgery (Table 1). The most commonly used instruments were Impact of vision impairment (used in 7 studies) and Low vision quality of life questionnaire (used in 4 studies).

**CONCLUSIONS:** Patients with glaucoma have significant impairment in their QoL, hence collection of such data is important for new medical products. PRO instruments such as Impact of vision impairment and Low vision quality of life questionnaire have commonly been used to generate evidence to show which therapies improve patient QoL.

**PSS33**

**BENEFITS OF PATIENT-REPORTED OUTCOMES IN DERMATOLOGY DRUG DEVELOPMENT**

Copley-Ferriman C1, Zelt S2, Clark M3, Gianasaksha A4
1Alexa Health Solutions, Am Arbor, MI, USA, 2GliaHealthOnline, Research Triangle Park, NC, USA

**OBJECTIVES:** A recent systematic literature review of randomized controlled dermatology-related trials showed that patient-reported efficacy outcomes (PROs) were mentioned in 35% of 45 trials. This study aims to characterize the benefits of PROs in drug development in dermatology from the patient, prescriber, regulator, payer, and manufacturer perspectives using a case study approach. The case studies were identified based on the use of PROs in pivotal clinical trials for the product. **METHODS:** A targeted literature review was conducted in PubMed from 2004 to 2014 for six products (Atopiclair for atopic dermatitis, Proin for dry skin, Trisodium citrate for acne, Stiefel’s liposome dipropionate gel for scalp psoriasis, pinemecolimus and tacrolimus for atopic dermatitis, and usteukinumab for psoriasis). Regulatory and health technology agency websites and publications were searched for documentation of PRO label claims and mentions.

**RESULTS:** For patients, inclusion of PROs ensured the full benefit of the product was demonstrated, including improvement in symptoms, quality of life, and/or treatment satisfaction. For prescribers, comparative trials reported PRO data information on each product’s benefits and risks and also which product was superior from the patient perspective. For regulators, for all except one of the six products, PROs were included in the product label. For payers, utility values based on PROs were used in cost-effectiveness evaluations for three of the six products. For manufacturers, the PROs generated label claims and many publications that allowed extensive public dissemination of product benefits.

**CONCLUSIONS:** Patient-reported assessment of the treatment impact on disease during drug development has many benefits for all stakeholders.

**PSS34**

**QUALITY ANALYSIS OF A NEW PATIENT REPORTED OUTCOME MEASURE FOR PSORIASIS TREATMENT (PROMPT)**

Kitchen H1, Cordingley L2, Gibbs C3, Young H4, Griffiths CE5, Bundy C6
1Akaxis International, Manchester, UK, 2University of Manchester and Manchester Academic Health Science Centre, Manchester, UK, 3University of Manchester, Manchester Academic Health Science Centre and Salford Royal NHS Foundation Trust, Salford, UK

**OBJECTIVES:** A draft patient-reported outcome measure for psoriasis treatment (PROMPT) was developed through patient interviews and comprised 51 items covering all domains of psoriasis disease. The objective of this work was to test the construct and content validity of the draft measure using the Rasch measurement model.

**METHODS:** Patient with chronic plaque psoriasis were identified and recruited according to pre-defined inclusion and exclusion criteria through psoriasis-specific secondary care clinics in the United Kingdom and two national patient organizations. Patients completed the draft measure at two time points, 14 days apart. Respondents with > 40% of missing data were removed from the final analyses. Data from each sub-scale were analyzed separately using RUMM2030 software to explore Rasch model fit, item difficulty, local dependence, item category thresholds, and differential item functioning (DIF) by age and gender. Where necessary, items were removed individually and the scale iteratively reassembled for fit and unidimensionality.

**RESULTS:** A sample of n=209 patients with chronic plaque psoriasis completed the draft measure. The initial fit to the model was poor, disordered category thresholds were identified for items in all scales. Post-hoc scoring from a 5-point Likert scale to a 3-point Likert scale improved model fit. Items which showed local dependence were removed in context of qualitative findings. Following removal of 11 items, all 7 scales demonstrated acceptable fit with the Rasch model (Chi Sq = 0.09 to 0.2). There was no evidence of DIF by age and gender.

**CONCLUSIONS:** The new measure, PROMPT, comprised 80 items in 6 independent, unidimensional scales, free from age or gender bias, with acceptable fit to the Rasch model. As such, the PROMPT has shown promise for use with patients with chronic plaque psoriasis in a clinical setting. The psychometric properties and scoring of the measure should be explored further and confirmed in future studies.